Citation: Sf. Rosebrough et al., CONTROLLED BLOOD CLEARANCE OF STREPTAVIDIN BY BIOCHEMICAL MODIFICATION WITH AN ISOTHIOCYANATE-TRIGALACTOSE DERIVATIVE, The Journal of nuclear medicine, 38(5), 1997, pp. 104-104
Citation: Sf. Rosebrough et Df. Hartley, BIOCHEMICAL MODIFICATION OF STREPTAVIDIN AND AVIDIN - IN-VITRO AND IN-VIVO ANALYSIS, The Journal of nuclear medicine, 37(8), 1996, pp. 1380-1384
Citation: M. Hashmi et Sf. Rosebrough, PHARMACOKINETICS AND BIODISTRIBUTION OF I-131-LABELED TRIGALACTOSE CONJUGATE OF STREPTAVIDIN, Drug metabolism and disposition, 24(2), 1996, pp. 267-269
Citation: Sf. Rosebrough et M. Hashmi, GALACTOSE-MODIFIED STREPTAVIDIN-GCLC ANTIFIBRIN MONOCLONAL-ANTIBODY CONJUGATES - APPLICATION FOR 2-STEP THROMBUS EMBOLUS IMAGING, The Journal of pharmacology and experimental therapeutics, 276(2), 1996, pp. 770-775
Citation: M. Hashmi et Sf. Rosebrough, SYNTHESIS, PHARMACOKINETICS, AND BIODISTRIBUTION OF GA-67 DEFEROXAMINEACETYL-CYSTEINYLBIOTIN, Drug metabolism and disposition, 23(12), 1995, pp. 1362-1367
Citation: Je. Seabold et Sf. Rosebrough, WILL A RADIOLABELED ANTIBODY REPLACE IN-111 PLATELETS TO DETECT ACTIVE THROMBUS, The Journal of nuclear medicine, 35(11), 1994, pp. 1738-1740
Citation: Sf. Rosebrough, PHARMACOKINETICS AND BIODISTRIBUTION OF RADIOLABELED AVIDIN, STREPTAVIDIN AND BIOTIN, Nuclear medicine and biology, 20(5), 1993, pp. 663-668
Citation: Sf. Rosebrough, PLASMA STABILITY AND PHARMACOKINETICS OF RADIOLABELED DEFEROXAMINE-BIOTIN DERIVATIVES, The Journal of pharmacology and experimental therapeutics, 265(1), 1993, pp. 408-415